Clinical Trials Browser

Has announcements × continuous erythropoietin receptor activator × Classical hematology × Clear all

NCT00717366 2017-09-08

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

Phase 2 Completed

64 enrolled 15 charts 1 FDA

Classical hematology

Renal Anemia